Skip to main content

Education First

Site section 6 of 12

Insulin resistance is loss of signal fidelity across tissues.

A research-first course on sugar-to-signal biology, insulin receptor pathways, GLUT4 trafficking, tissue-specific resistance, lipid and organelle stress, inflammatory crosstalk, downstream excess-glucose chemistry, islet compensation, measurement, and catalog boundaries.

Learning progress

Progress is private to this browser.

Primary learning surface

Glucose disposal model

How a saturating response to an insulin signal flattens as sensitivity falls, so that the same disposal needs more signal, the mechanism behind compensation indices.

Modeled
1.00Unitless. How readily the insulin signal drives disposal; lower is less sensitive.
10.0Arbitrary units, 0 to 20. The point on the curve the cursor reads.
00.250.500.75105101520glucose disposal (fraction of model ceiling)insulin signal, arbitrary unitshalf-maximal (model)

Modeled disposal

91% of ceiling

at the scrubbed insulin signal

Half-maximal signal

1.00arbitrary

1 / Si; 1.00 × the signal Si = 1 needs

Signal for 90 percent

9.0arbitrary

9 / Si

Disposal at the plot edge

95% of ceiling

at an insulin signal of 20

An intermediate sensitivity

At Si 1.00 the model reaches half of its ceiling at an insulin signal of 1.00, 1.00 times the signal Si = 1 needs, reaches 90 percent at 9.0, and reads 95 percent at the edge of the plot. At the scrubbed signal of 10.0 disposal is 91 percent of the ceiling. Lower Si to watch the curve flatten and the half-maximal point move right.

Insulin sensitivity 1.00, insulin signal 10.0. Modeled disposal 91 percent of the ceiling. Half of the ceiling needs 1.00 times the insulin of Si 1; 90 percent needs a signal of 9.0; the plot edge reads 95 percent.

Method and sources

disposal = Si × x / (1 + Si × x); a fraction f of the ceiling is reached at x = f / ((1 − f) × Si)

What it shows: A Michaelis-style saturation: disposal rises with the insulin signal x and approaches the model ceiling of 1. Si sets how quickly it climbs; the half-maximal point 1 / Si and the 90 percent point 9 / Si move right as Si falls.

How to read it: The curve is the model at the set Si over an insulin signal of 0 to 20; the cursor reads disposal at the scrubbed signal. The dashed reference marks the half-maximal point and the dashed top line the ceiling the curve approaches. The half-maximal signal is also the compensation multiplier against Si = 1, whose half-maximal signal is 1.

Assumptions: One saturating step with no threshold, no time course and no counter-regulation. The insulin axis is in arbitrary units and disposal is a fraction of the model’s own ceiling. Clinical indices such as HOMA-IR are estimated from fasting glucose and insulin by a different, calibrated model.

Si and the insulin signal are yours to set, not measured for you or any lot; the reading is not a HOMA-IR result, not a diagnosis, not any product’s effect, and not prevention, treatment or use guidance.

A saturating curve rising from the origin and bending toward a dashed ceiling, on ticked axes, with a dashed reference at its half-maximal point and a cursor at the scrubbed insulin signal.

Check yourself

Do not turn mechanism into advice.

A learner sees glucose, insulin signaling, adipose flux, and islet feedback and wants a personal plan. The course must force the question back to mechanism, readout type, and boundary.

Choose the next move

Pick an answer to see why.

Course spine

Fourteen chapters, no skipped machinery.

The course starts with normal glucose and insulin biology, then builds toward tissue-specific resistance, downstream glucose-exposure chemistry, feedback loops, measurement limits, and catalog boundaries.

  1. 01 / Orientation

    Define insulin resistance as tissue-specific loss of insulin-signal fidelity, not a single on/off state.

  2. 02 / Sugar to signal

    Trace absorbable carbohydrate exposure through glucose appearance, insulin secretion, and tissue fuel partitioning without giving dietary guidance.

  3. 03 / Receptor network

    Map insulin receptor, IRS, PI3K, PIP3, AKT, AS160/TBC1D4, FOXO1, GSK3, mTOR, MAPK, and phosphatase control nodes.

  4. 04 / GLUT4 trafficking

    Explain insulin-stimulated GLUT4 vesicle movement in skeletal-muscle and adipose model systems.

  5. 05 / Tissue atlas

    Separate skeletal muscle, liver, adipose tissue, islet, endothelium, immune-stromal, brain, and bone contexts.

  6. 06 / Initiation

    Describe adipose buffering limits, lipolysis escape, fatty-acid flux, and ectopic lipid as early system stressors.

  7. 07 / Liver divergence

    Explain selective hepatic insulin resistance: incomplete glucose-output suppression with persistent lipid-program signals.

  8. 08 / Organelle stress

    Connect DAG, ceramide, PKC, mitochondria, ROS, ER stress, and incomplete substrate handling to signaling interference.

  9. 09 / Inflammatory crosstalk

    Show how JNK, IKK/NF-kB, SOCS, PTP1B, mTOR/S6K, cytokines, and nutrient-stress nodes can intersect IRS signaling.

  10. 10 / Sustained glucose exposure

    Teach nonenzymatic glycation, AGE/RAGE, polyol flux, hexosamine signaling, PKC, oxidative stress, capillary biology, immune shifts, bone matrix context, retina, kidney-like barriers, nerves, and beta-cell glucotoxicity.

  11. 11 / Islet feedback

    Place hyperinsulinemia, beta-cell compensation, secretory load, insulin clearance, and decompensation into a feedback map.

  12. 12 / Measurement

    Match readout categories to the mechanism they can observe and the inference they cannot prove alone.

  13. 13 / Catalog boundary

    Keep catalog records limited to identity, structural context, analytical documentation, and reading a certificate.

  14. 14 / Capstone

    Assemble a full map from carbohydrate exposure to tissue-specific resistance, downstream glucose exposure, feedback loops, and measurement limits.

What this course covers

One biological chain, taught in order.

Normal insulin action comes first, then tissue-specific resistance, then the downstream chemistry of excess glucose exposure. Catalog material stays outside the mechanism claim, and no chapter offers diagnosis, prevention, management, supplement, dosing, or route guidance.

Insulin signaling

Receptor autophosphorylation, IRS docking, PI3K/PIP3, PDK1/mTORC2-AKT, AS160/TBC1D4, FOXO1, GSK3, mTOR, MAPK, PTEN, and PTP1B, in sequence.

Tissue by tissue

Muscle glucose disposal, hepatic glucose output, adipose anti-lipolysis, islet feedback, endothelial signaling, immune-stromal tone, and bone matrix context, each on its own.

Glucose-exposure chemistry

The downstream layer: glycation, AGE/RAGE, the polyol pathway, hexosamine flux, PKC activation, oxidative stress, capillary barriers, retina, nerve, kidney-like filtration, and bone collagen effects.

What each readout can establish

Clamps, tracers, OGTT curves, phosphoproteomics, lipidomics, cell assays, imaging, and histology, each tied to what it can and cannot establish.

Chapter 01

Insulin resistance is not one broken switch.

Define insulin resistance as tissue-specific loss of insulin-signal fidelity, not a single on/off state.

Signal fidelity

The useful question is not whether insulin exists. It is whether each tissue receives, routes, and answers the signal with the right strength and timing.

Tissue divergence

Muscle, liver, adipose tissue, islet, endothelium, immune-stromal tissue, bone, retina-like barriers, and nerves have different insulin and glucose-exposure problems.

Feedback

Hyperinsulinemia, fatty-acid spillover, inflammation, capillary stress, glucose-derived chemistry, and beta-cell load can become self-reinforcing loops.

Chapter 02

From sugar exposure to insulin signal.

Trace absorbable carbohydrate exposure through glucose appearance, insulin secretion, and tissue fuel partitioning without giving dietary guidance.

  1. Signal 01

    Digestion and appearance

    Absorbable carbohydrate can appear in circulation as glucose. Sucrose also carries fructose, which routes through intestinal and hepatic handling rather than the same insulin-regulated GLUT4 pathway.

  2. Signal 02

    Insulin pulse

    Rising glucose increases beta-cell secretory demand. Insulin then helps coordinate fuel storage, glucose uptake, anti-lipolysis, and hepatic glucose-output suppression.

  3. Signal 03

    Tissue partitioning

    Muscle, liver, adipose tissue, endothelium, immune cells, bone cells, neural tissue, and islets do not experience the same insulin job or the same stress threshold.

  4. Signal 04

    Repeated exposure

    When exposure is high, repeated, or paired with impaired buffering, the system can shift toward hyperinsulinemia, lipid spillover, oxidative stress, and glucose-derived chemical stress.

The rising-then-saturating shape that links a growing input to a bounded response recurs across this biology: glucose appearance driving insulin secretion, insulin signal driving disposal. Drive the general model below to feel that shape. The axes carry no real numbers and it is not measured data for glucose, insulin, or any lot.

Dose-response, the model

How a response climbs from a threshold to a ceiling as concentration rises: EC50 shifts the curve, the Hill slope changes its width, and Emax sets the ceiling; the rise from a tenth to nine tenths spans 81^(1/n) in concentration.

Modeled
1.00The model’s own maximum response, as a fraction of a full ceiling.
1.50Steepness of the climb; higher n narrows the rise.
midWhere the half-maximal point sits on the numberless concentration axis.
midScrub here or drag on the plot; the axis carries no unit and no number.

Response

50%

on the response axis, the value under the needle (climbing); 50 % of the ceiling you set

Ten-to-ninety span

18.72fold

81^(1/n) in concentration; the dashed n = 1 reference spans 81 fold

At the half-maximal point

The scrubbed concentration sits at the EC50 you set, so the model returns half of its own ceiling (50 percent here, at the scrub’s resolution). This is the inflection of the curve on the log-concentration axis, where the climb is at its steepest.

In this model, with the scrubbed concentration at the EC50 you set, the response axis reads 50 percent, which is 50 percent of the ceiling you set. EC50 and slope are parameters you set, not measured for this lot.

Method and sources

response = Emax / (1 + 10^(n (log EC50 − log C)))

What it shows: The general S-shaped relationship many chemical sequences are described by: as concentration rises the response stays near zero, then climbs, then flattens at a ceiling. The midpoint of the climb is the EC50, the half-maximal point.

How to read it: Move EC50 to shift the whole curve left or right, raise the Hill slope n to sharpen the climb (the dashed curve keeps the slope of one for reference), lower Emax to drop the ceiling, and scrub on the plot or with the control to read the model fraction at any concentration. The concentration axis carries no numbers on purpose: the shape is the point.

Assumptions: A single Hill relationship with one EC50 and one slope; no measured concentration, response, EC50 or ceiling for any lot; no variance, so no uncertainty band is drawn.

Sources: None stated: the parameters are yours to set.
A model of the general concentration-response relationship that you drive. Parameters are yours to set; not measured for any lot; not an efficacy or dosing claim. No uncertainty band is drawn: this model has no fit and no stated variance to draw one from.

A sigmoid on a numberless concentration axis rising from near zero to the ceiling you set. A caret on the axis marks the EC50 you set; a bracket above the field spans the rise from a tenth to nine tenths of the ceiling; the needle sits at the concentration you scrubbed. When the Hill slope is not one, a dashed reference curve shows the same EC50 and ceiling at a slope of one.

Chapter 03

The receptor network sets the first gate.

Map insulin receptor, IRS, PI3K, PIP3, AKT, AS160/TBC1D4, FOXO1, GSK3, mTOR, MAPK, and phosphatase control nodes.

  1. 01Insulin receptor activation creates phosphorylated docking sites.
  2. 02IRS proteins recruit PI3K, building PIP3 at the membrane.
  3. 03PDK1 and mTORC2 help activate AKT at key phosphorylation sites.
  4. 04AKT routes signals toward GLUT4 trafficking, glycogen synthesis, FOXO1 control, protein synthesis context, and survival pathways.
  5. 05MAPK and mitogenic branches run in parallel and can diverge from metabolic signaling.
  6. 06Phosphatases, lipid phosphatases, inflammatory kinases, and nutrient kinases tune the signal up or down.

Chapter 04

GLUT4 trafficking is cellular logistics.

Explain insulin-stimulated GLUT4 vesicle movement in skeletal-muscle and adipose model systems.

Storage

In skeletal-muscle and adipose model systems, GLUT4 is stored in specialized intracellular vesicles before insulin stimulation.

Signal routing

AKT can regulate AS160/TBC1D4 and Rab-like trafficking machinery, helping vesicles move toward the membrane.

Docking and fusion

Vesicles dock and fuse with the plasma membrane, increasing surface transporter availability in an insulin-responsive state.

Resistance point

Reduced signaling at IRS, PI3K, AKT, AS160, cytoskeleton, or vesicle-fusion nodes can lower insulin-stimulated glucose disposal.

Chapter 05

Every tissue answers insulin differently.

Separate skeletal muscle, liver, adipose tissue, islet, endothelium, immune-stromal, brain, and bone contexts.

Skeletal muscle

Largest insulin-stimulated glucose-disposal compartment in many clamp models. Key issues include GLUT4 translocation, glycogen synthesis, intramyocellular lipid, DAG/PKCtheta, ceramide, mitochondrial substrate pressure, and capillary delivery.

Liver

Insulin normally restrains hepatic glucose production and coordinates glycogen and lipid routing. Selective resistance can leave glucose-output suppression impaired while lipid programs remain active.

Adipose tissue

Insulin suppresses lipolysis and supports lipid storage. When anti-lipolysis is blunted, fatty acids and glycerol can spill into circulation and feed liver and muscle stress.

Pancreatic islet

Beta cells increase secretory output when insulin demand rises. Compensation can maintain system output for a time, while secretory load can stress ER, mitochondria, granule processing, and proinsulin conversion.

Endothelium

Insulin signaling has PI3K-NO and MAPK/endothelin-like branches. Resistance can become branch-selective, changing vascular tone, adhesion biology, glycocalyx state, and capillary recruitment.

Immune-stromal niche

Macrophages, neutrophils, lymphocytes, fibroblasts, and stromal cells can read lipid, glucose, cytokine, hypoxia, and matrix cues, then feed stress signals back into metabolic tissues.

Bone matrix

Bone is not passive storage. High-glucose exposure can alter collagen chemistry, osteoblast and osteoclast signaling, marrow immune tone, and matrix quality in model systems.

Neural and ocular barriers

Nerves, retinal capillaries, lens-like matrix, and barrier tissues are exposed to glucose without relying on GLUT4 in the same way as muscle. This makes local glucose chemistry and capillary stress especially important.

Chapter 06

Many loops begin with buffering failure.

Describe adipose buffering limits, lipolysis escape, fatty-acid flux, and ectopic lipid as early system stressors.

Adipose buffering limit

When lipid storage cannot buffer incoming fuel cleanly, adipocytes can enlarge, remodel matrix, change oxygen tension, and recruit immune-stromal signaling.

Lipolysis escape

Insulin normally restrains ATGL/HSL/perilipin-linked lipolysis. Resistance can raise fatty-acid and glycerol flux even when insulin is present.

Ectopic lipid

Lipid intermediates in liver and muscle, including DAG and ceramide species, can interfere with insulin signaling through PKC, PP2A, or AKT-related mechanisms depending on context.

Hyperinsulinemia

Higher insulin output can compensate for reduced sensitivity, but persistent high demand can also become part of the feedback architecture being studied.

Chapter 07

The liver can diverge from the simple switch model.

Explain selective hepatic insulin resistance: incomplete glucose-output suppression with persistent lipid-program signals.

FOXO1 control

AKT normally restrains FOXO1-linked gluconeogenic gene programs. Reduced signal fidelity can weaken that brake.

Substrate inflow

Adipose glycerol and fatty-acid flux can provide substrate and energy context for hepatic glucose production and lipid output.

Selective resistance

Glucose-output restraint and lipogenic pathway behavior can diverge. That is why liver insulin resistance cannot be read as one simple failed switch.

VLDL and lipid context

Hepatic lipid routing, de novo lipogenesis context, and export pathways can become coupled to systemic insulin demand and substrate pressure.

Chapter 08

Lipid and organelle stress interfere with the signal.

Connect DAG, ceramide, PKC, mitochondria, ROS, ER stress, and incomplete substrate handling to signaling interference.

DAG and PKC

Membrane-associated DAG species can activate PKC isoforms that reduce proximal insulin-signal fidelity in liver and muscle models.

Ceramide

Ceramide species can intersect AKT signaling, phosphatase activity, mitochondrial state, and inflammatory tone in context-specific ways.

Mitochondrial pressure

Substrate overload can increase incomplete fatty-acid oxidation signals, acylcarnitine patterns, redox pressure, and ROS context.

ER stress and UPR

IRE1, PERK, ATF6, XBP1 splicing, CHOP, and eIF2alpha-linked pathways can connect protein-folding burden to inflammatory and metabolic signals.

Chapter 09

Inflammatory and nutrient stress can brake IRS signaling.

Show how JNK, IKK/NF-kB, SOCS, PTP1B, mTOR/S6K, cytokines, and nutrient-stress nodes can intersect IRS signaling.

  1. 01TNF-like and IL-6-like cytokine signals can activate stress pathways in specific tissue contexts.
  2. 02JNK and IKK/NF-kB pathways can interfere with IRS function, including inhibitory phosphorylation and altered protein abundance.
  3. 03SOCS proteins and PTP1B can dampen signaling by targeting receptor and IRS layers.
  4. 04mTOR/S6K nutrient feedback can reduce upstream insulin signaling when nutrient tone is persistently high.
  5. 05Macrophage, adipocyte, hepatocyte, myocyte, endothelial, and stromal signals reinforce each other in tissue-specific loops.

Chapter 10

Sustained elevated glucose has downstream chemistry.

Teach nonenzymatic glycation, AGE/RAGE, polyol flux, hexosamine signaling, PKC, oxidative stress, capillary biology, immune shifts, bone matrix context, retina, kidney-like barriers, nerves, and beta-cell glucotoxicity.

Precision note

It is repeated chemical exposure, not a simple switch.

The accurate mechanism is nonenzymatic glycation, carbonyl stress, altered redox state, osmotic flux, kinase activation, matrix modification, and capillary signaling. Bone and immune cells are part of that network, but the biology is altered immune-cell function and osteoimmune crosstalk, not a one-step immune command.

Nonenzymatic glycation

Glucose and reactive carbonyl intermediates can modify long-lived proteins, lipids, and nucleic-acid-adjacent structures, forming early glycation products and advanced glycation end products.

AGE/RAGE signaling

AGE-modified matrix and circulating ligands can engage RAGE-like receptors, linking oxidative stress, NF-kB-like transcription, endothelial activation, and immune-cell signaling.

Polyol pathway

Excess intracellular glucose can route through aldose reductase to sorbitol, consuming NADPH and changing osmotic and redox state, especially in susceptible tissues.

Hexosamine flux

Glucose-derived substrates can feed O-GlcNAc and transcriptional control layers, altering signaling proteins and gene programs.

DAG-PKC activation

High glucose can increase DAG and PKC activity in vascular and metabolic cells, affecting permeability, blood-flow signaling, adhesion, and extracellular matrix programs.

Oxidative and carbonyl stress

Mitochondrial redox pressure and reactive carbonyl species create a shared stress layer that can amplify glycation, inflammation, and endothelial dysfunction.

Retina and lens-like tissues

Ocular tissues experience glucose chemistry directly. Polyol flux, AGE accumulation, oxidative stress, endothelial activation, pericyte-like cell stress, and capillary barrier changes can appear in model systems.

Kidney-like filtration barriers

Glomerular-like capillaries, basement membrane, podocyte-like cells, mesangial-like cells, and glycocalyx can respond to AGE/RAGE, PKC, oxidative stress, and matrix-production signals.

Peripheral nerves

Axons and microvessels can be affected by polyol flux, mitochondrial stress, reduced trophic support, ischemia-like microvascular context, and altered Schwann-cell biology in research models.

Capillary systems

Endothelial glycocalyx, nitric-oxide signaling, basement membrane thickness, leukocyte adhesion, permeability, and capillary recruitment are central to how glucose exposure spreads across organs.

Immune cells

High-glucose environments can alter neutrophil chemotaxis and oxidative burst, macrophage polarization, inflammasome tone, cytokine output, phagocytosis, and resolution behavior. This is immune dysregulation, not a one-step decrease in immunity.

Bone and marrow niche

The precise bone story is not glucose telling immunity to switch off. High-glucose and AGE exposure can stiffen collagen matrix, engage RAGE-like signaling, alter osteoblast and osteoclast function, and change marrow immune-stromal crosstalk.

Beta cells

Chronic glucose exposure can create glucotoxic stress: ER load, mitochondrial redox pressure, altered granule processing, proinsulin conversion stress, and reduced first-phase response in model systems.

Liver and adipose feedback

Glucose-derived lipid routing, fructose-linked hepatic substrate handling, adipose insulin resistance, and fatty-acid spillover can reinforce each other with hyperinsulinemia and inflammatory tone.

Chapter 11

Islet compensation is useful until demand outruns capacity.

Place hyperinsulinemia, beta-cell compensation, secretory load, insulin clearance, and decompensation into a feedback map.

Compensation

When peripheral tissues respond less strongly, beta cells can raise insulin output so the wider system still receives enough signal.

Clearance

Measured insulin depends on secretion and clearance. Liver insulin extraction and peripheral clearance can change the interpretation of circulating insulin.

Secretory load

Persistent demand stresses ER folding, mitochondria, calcium handling, granule maturation, and proinsulin-to-insulin conversion.

Decompensation

When compensation no longer matches demand, the system can show higher glucose exposure, more glucotoxicity, and weaker beta-cell output. This page explains the mechanism, not diagnosis.

Chapter 12

Measurement depends on the mechanism question.

Match readout categories to the mechanism they can observe and the inference they cannot prove alone.

Hyperinsulinemic euglycemic clamp

Can show: Estimate insulin-stimulated glucose disposal under controlled research conditions.

Cannot prove alone: By itself, localize the molecular defect, diagnose a person from a course page, or prove an intervention effect.

Tracer hepatic glucose production

Can show: Separate endogenous glucose production from disposal and substrate flux.

Cannot prove alone: Replace tissue assays or prove the complete liver signaling state alone.

OGTT or mixed-meal curves

Can show: Show glucose, insulin, connecting-segment (C) chain, incretin, and clearance dynamics over time.

Cannot prove alone: Define the exact tissue mechanism without modeling and additional measurements.

HOMA-like indices

Can show: Summarize fasting glucose-insulin relationships in population or screening research.

Cannot prove alone: Measure muscle glucose disposal, beta-cell reserve, tissue lipid stress, or clinical status alone.

Phosphoproteomics and signaling assays

Can show: Read IR, IRS, AKT, AS160, GSK3, FOXO1, JNK, IKK, mTOR/S6K, and eNOS-like signal states.

Cannot prove alone: Stand in for whole-body physiology without tissue and time context.

Lipidomics and metabolomics

Can show: Profile DAG, ceramide, acylcarnitines, amino-acid patterns, redox pools, and glucose-derived metabolites.

Cannot prove alone: Prove direction of causality without experimental design.

AGE, RAGE, and carbonyl-stress assays

Can show: Measure glycation burden, matrix modification, and receptor-linked inflammatory context.

Cannot prove alone: Prove tissue damage, diagnosis, or product-related change alone.

Histology and imaging

Can show: Localize capillary structure, matrix deposition, immune-cell clusters, adipocyte size, liver fat, and bone matrix context.

Cannot prove alone: Replace controlled functional readouts or establish human outcomes from a figure.

Chapter 13

Catalog records stay outside the outcome claim.

Keep catalog records limited to identity, structural context, analytical documentation, and reading a certificate.

This course intentionally avoids catalog recommendations. The topic is too easy to misread as glucose, insulin, appetite, body-weight, or disease-outcome guidance. Catalog records belong in identity, structure, analytical release, and COA-literacy lanes only.

Boundary

Identity only

Catalog records document chemical-sequence identity, format, and lot documentation. They do not establish effects on insulin, glucose, appetite, body weight, metabolic health, or any human or veterinary outcome.

Boundary

Structure only

Receptor-family or pathway imagery is structural context. It is not a binding claim, outcome claim, use instruction, or evidence that a catalog item changes a biological pathway.

Boundary

Reading a certificate

Analytical documents answer identity, purity, contaminant, and release questions. They do not answer physiology, diagnosis, treatment, prevention, or suitability-for-use questions.

Chapter 14

Capstone: draw the full insulin-resistance map.

Assemble a full map from carbohydrate exposure to tissue-specific resistance, downstream glucose exposure, feedback loops, and measurement limits.

  1. 01Start with exposure: glucose appearance, insulin pulse, tissue fuel partitioning, and repeated substrate load.
  2. 02Map the receptor layer: IR, IRS, PI3K, PIP3, AKT, AS160, FOXO1, GSK3, mTOR, MAPK, phosphatases, and stress kinases.
  3. 03Place tissue divergence: muscle disposal, liver output, adipose anti-lipolysis, islet compensation, endothelial signaling, immune-stromal tone, neural/ocular barriers, and bone matrix context.
  4. 04Add initiation stress: adipose buffering limit, fatty-acid flux, ectopic lipid, DAG, ceramide, mitochondrial pressure, ER stress, and redox load.
  5. 05Add sustained-glucose chemistry: nonenzymatic glycation, AGE/RAGE, polyol, hexosamine, PKC, oxidative stress, carbonyl stress, and capillary glycocalyx changes.
  6. 06Trace downstream compartments: retina/lens-like tissue, kidney-like filtration barrier, nerve, capillary wall, immune cells, bone matrix, beta cells, liver, and adipose feedback.
  7. 07Choose readouts that fit the question and state what each cannot prove alone.
  8. 08Keep catalog documentation outside the mechanism claim.

Selected references

Educational biology context only. This course explains research concepts in sustained hyperglycemia, microvascular stress, glycation, tissue remodeling, and organ-system readouts. Not medical advice, diagnostic evidence, treatment guidance, prevention guidance, dosing guidance, administration guidance, wellness guidance, weight-loss guidance, supplement guidance, or evidence that any catalog item changes glucose handling, disease outcomes, or any biological outcome. Insulin-resistance testing and diagnosis belong to licensed health care professionals. This course explains research concepts and readout categories only. Catalog context, if present, is limited to identity, structural context, analytical documentation, and reading a certificate.

Editorial scope: chemical identity, experimental context, analytical methods, source quality and regulatory boundaries. Source references and stated limitations form part of the material; they should remain attached to quotations or summaries.

Biological systems path